

## ASX RELEASE

### Volpara to present at TechKnow Invest Roadshow webinar

Wellington, NZ, 7<sup>th</sup> May 2020: Volpara Health Technologies Limited (Volpara; ASX: VHT), a medical technology company whose cancer screening software platform assists in the delivery of personalized patient care, is pleased to provide an opportunity for shareholders and investors to join a virtual presentation by CEO Dr Ralph Highnam, who will present at the TechKnow Invest Roadshow webinar to be held on Tuesday, 12 May 2020.

This also serves as a reminder that SPP closes on Monday 11 May.

The presentation will cover topics such as:

- The latest 4C cash results
- The latest SaaS metrics
- The unaudited FY results
- The rationale for the recent capital raise

The event is free and investors can register online to view the presentation here:

[https://us02web.zoom.us/webinar/register/WN\\_H8dwnG-3Rni0cMPfep96eg](https://us02web.zoom.us/webinar/register/WN_H8dwnG-3Rni0cMPfep96eg)

AFTER registering you will receive an email with all login details (a website link or phone dial in details).

**Event:** TechKnow Invest Roadshow webinar

**Presenting:** Dr Ralph Highnam, CEO

**Time/date:** 1:30pm AEST, Tuesday 12 May

### Authorisation and additional Information

This announcement was authorised by the CEO.

For further information, please contact:

Ralph Highnam, CEO  
Volpara Health Technologies  
[ralph.highnam@volparasolutions.com](mailto:ralph.highnam@volparasolutions.com)  
t: +64 21 149 0541

Kyahn Williamson  
WE Communications  
[kwilliamson@we-worldwide.com](mailto:kwilliamson@we-worldwide.com)  
t: +61 3 9866 4722

### About Volpara Health Technologies Limited (ASX: VHT)

VHT is a MedTech SaaS company founded in 2009 on research originally conducted at Oxford University. VHT's clinical functions for screening clinics provide feedback on breast density, compression, dose, and quality, while its enterprise-wide practice software management helps with productivity, compliance, reimbursement, and patient tracking.

VHT's technology and services have been used by customers and/or research projects in 38 countries and are supported by numerous patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. Since its listing on the ASX in April 2016, VHT has raised A\$95 million, including A\$55 million in June 2019. VHT is based in Wellington, New Zealand.

At the end of June 2019, VHT acquired MRS, a company based in Seattle, WA. MRS provides mammography reporting systems to over 1,600 breast clinics and hospitals, and provides to VHT a much stronger US presence, experienced local headquarters, and accelerated sales through cross-selling opportunities.

Further information about Volpara can be found at <https://volparasolutions.com>